The European Commission has expanded the indication for MenQuadfi to include infants from 6 weeks of age, offering earlier protection against invasive meningococcal disease—a bacterial infection known to cause permanent hearing loss in survivors....
Continue reading at Hearing Review
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiologists; this is a public-health vaccination approval — awareness of meningococcal disease as a cause of acquired hearing loss is already established, and vaccine prescribing sits outside audiology scope of practice.
Earlier vaccination against meningococcal disease could reduce the incidence of meningitis-related acquired hearing loss in infants, potentially lowering the population of children who need audiological rehabilitation.
- 01European Commission expanded MenQuadfi's approved age range to infants from 6 weeks of age.
- 02Invasive meningococcal disease is a leading preventable cause of permanent acquired sensorineural hearing loss in children.
- 03Earlier vaccination closes a protection gap in the first months of life, previously the highest-risk window.
- 04The approval is a regulatory decision by the European Commission, not a clinical audiology guideline change.
- 05Audiologists should be aware of meningitis history when assessing hearing loss aetiology in paediatric patients.
Invasive meningococcal disease is a leading cause of permanent acquired hearing loss.
guidelinesupportedMenQuadfi has been approved by the European Commission for use in infants from 6 weeks of age.
press releasesupported